Free Trial
OTCMKTS:MYCOF

Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis

Mydecine Innovations Group logo
$0.0027 0.00 (0.00%)
As of 09/12/2025

About Mydecine Innovations Group Stock (OTCMKTS:MYCOF)

Key Stats

Today's Range
$0.0027
$0.0027
50-Day Range
N/A
52-Week Range
$0.0007
$0.0115
Volume
37 shs
Average Volume
7,350 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MYCOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MYCOF Stock News Headlines

Mydecine Innovations Group Inc - Delisting From AQSE
What President Trump’s Executive Order 14154 means for your money
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.tc pixel
Mydecine Innovations Group Inc (MYCOF)
Mydecine Innovations Group Inc - Suspension of Trading
Mydecine Innovations Group Inc. (MYCOF)
See More Headlines

MYCOF Stock Analysis - Frequently Asked Questions

Mydecine Innovations Group's stock was trading at $0.0028 at the beginning of 2025. Since then, MYCOF stock has decreased by 3.6% and is now trading at $0.0027.

Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) announced its quarterly earnings results on Tuesday, November, 16th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.50.

Mydecine Innovations Group shares reverse split on the morning of Thursday, April 21st 2022.The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2021
Today
9/13/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Candy & Soda
Current Symbol
OTCMKTS:MYCOF
CIK
N/A
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:MYCOF) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners